Both Cellectis S.A. (NASDAQ:CLLS) and Audentes Therapeutics Inc. (NASDAQ:BOLD) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	21.43M	38.18	78.69M	-2.11	0.00
Audentes Therapeutics Inc.	N/A	0.00	128.82M	-2.72	0.00

In table 1 we can see Cellectis S.A. and Audentes Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-367.20%	-23%	-18.8%
Audentes Therapeutics Inc.	0.00%	-36.6%	-33.9%

Liquidity

The Current Ratio and a Quick Ratio of Cellectis S.A. are 11.2 and 11.2. Competitively, Audentes Therapeutics Inc. has 14.8 and 14.8 for Current and Quick Ratio. Audentes Therapeutics Inc.’s better ability to pay short and long-term obligations than Cellectis S.A.

Analyst Ratings

The table given features the ratings and recommendations for Cellectis S.A. and Audentes Therapeutics Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	2	1	2.33
Audentes Therapeutics Inc.	0	0	0	0.00

Cellectis S.A.’s upside potential is 80.58% at a $35.25 average target price.

Institutional & Insider Ownership

The shares of both Cellectis S.A. and Audentes Therapeutics Inc. are owned by institutional investors at 29.4% and 0% respectively. Competitively, Audentes Therapeutics Inc. has 1.3% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%
Audentes Therapeutics Inc.	18.9%	40.28%	43.46%	-2.66%	2.02%	63.18%

For the past year Cellectis S.A.’s stock price has smaller growth than Audentes Therapeutics Inc.

Summary

On 7 of the 10 factors Cellectis S.A. beats Audentes Therapeutics Inc.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.